Exclusive Summary

• - First-line for invasive candidiasis per major guidelines, with full 70 mg loading + 50 mg maintenance strengths aligning to standard dosing.
• - US-FDA and EU-EMA GMP certified and registered in the US and EU-27, enabling rapid entry via reliance pathways across regions.
• - Post-expiry, mature generic competition delivers 40–70% savings vs originator, fitting hospital tenders and pooled procurement.
• - Rising antifungal resistance (e.g., Candida auris) and ICU/hematology demand sustain strong need for echinocandins like caspofungin.
• - Multi-indication inpatient use (invasive candidiasis, empiric therapy in febrile neutropenia, salvage in aspergillosis) supports stable volume.